|
|
|
|
|
|
||
|
|
||
|
|
|
overview | leadership | founders | scientific advisory board | investors leadershipThe experienced management team at Agios is comprised of proven leaders with a track record of developing important new therapeutics and of leading respected and successful life sciences companies. Our team brings a full range of operating and leadership experience across the critical disciplines — science, technology, business development, marketing and finance — and is devoted to building Agios into a leading biopharmaceutical company. management
Dr. David Schenkein joined Agios in August 2009 as the Chief Executive Officer. Prior to joining Agios, Dr. Schenkein was the Senior Vice President, Clinical Hematology/Oncology at Genentech, Inc. in San Francisco where he was responsible for leading the medical and scientific strategies for their BioOncology portfolio. He has been a Medical Oncologist and Hematologist for over 20 years and while in San Francisco was an Adjunct Clinical Professor of Medicine Oncology at Stanford University School of Medicine. Prior to joining Genentech, Dr. Schenkein spent 17 years in academic and clinical medicine as an attending physician in Hematology Oncology at the Tufts-New England Medical Center in Boston, where he was an associate professor and held the position of director of the Cancer Center. From 2001- 2006, he worked at Millennium Pharmaceuticals where he served as the Senior Vice President of Clinical Research, overseeing the clinical development of Velcade, a first-in class cancer therapy now approved to treat multiple myeloma and non-Hodgkins lymphoma. Dr. Schenkein holds a BA in Chemistry from Wesleyan University and an MD from the State University of New York Upstate Medical School.
Duncan Higgons joined Agios in May 2009 as the Chief Operating Officer. Prior to joining Agios, Mr. Higgons worked at Archemix Corporation from 2006 – 2009 where he most recently served as President, Chief Operating Officer and interim C.E.O. Prior to Archemix, he worked as the Chief Commercial Officer at TransForm Pharmaceuticals which was acquired by Johnson & Johnson Company. Mr. Higgons has also previously held positions at Alkermes, Inc. including Senior Vice President of Business Development and Marketing, and at Eli Lilly & Co. where he served in a variety of senior sales and marketing functions, and at Baxter International. He holds a B.Sc. in Mathematics from King’s College University of London, and an MSc. Econ. from London Business School.
Dr. Su brings more than seventeen years of organization, project management and scientific experience in the biotechnology industry. Most recently, he served as General Director and Vice President of the Biomedical Engineering Research Laboratory (BEL) at ITRI in Taiwan. Prior, he spent 14 years in a number of roles, concluding his tenure as Program Executive and Vice President of the Novartis Kinase Collaboration for Vertex Pharmaceuticals.
Jeff joined Agios full time in September, 2008 as the Head of Chemistry. Prior to joining Agios, Dr. Saunders worked as a consultant at Elixir Pharmaceuticals where he managed all chemistry and related intellectual property for 5 years, and as a consultant for Agios for one and a half years. He has also held positions at Vertex Pharmaceuticals, where he worked for approximately 14 years as an Investigator and eventually a Principal Investigator/Project Head for multiple programs, and at the Squibb Institute for Biomedical Research (now Bristol Myers Squibb) where he was a Research Scientist. Jeff received his Bachelor of Arts in Chemistry from Hope College in Michigan, earned his Ph.D. in Synthetic Organic Chemistry at the University of South Carolina and held a NIH post-doctoral fellowship at the University of Pennsylvania. board of directorsBob Nelsen – ARCH Venture Partners |
|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
design by Digizyme | |
|
© 2010 Agios Pharmaceuticals |
David Schenkein, MD
Duncan Higgons
Shin-San Michael Su, Ph.D.
Jeff Saunders, Ph.D.